Robert Driscoll
Stock Analyst at Wedbush
(4.45)
# 1,168
Out of 4,644 analysts
367
Total ratings
46.1%
Success rate
10.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Reiterated: Buy | $33 → $39 | $26.13 | +49.25% | 12 | Aug 12, 2026 | |
| REPL Replimune Group | Upgraded: Buy | $12 → $19 | $15.31 | +24.10% | 21 | Aug 7, 2026 | |
| RCUS Arcus Biosciences | Reiterated: Buy | $41 → $43 | $28.88 | +48.89% | 25 | Aug 6, 2026 | |
| BDTX Black Diamond Therapeutics | Reiterated: Buy | $14 | $2.04 | +587.96% | 15 | Aug 6, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $192 → $201 | $207.42 | -3.10% | 25 | Aug 6, 2026 | |
| ARVN Arvinas | Maintained: Hold | $11 → $12 | $8.81 | +36.21% | 27 | Aug 5, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Buy | $58 → $60 | $36.84 | +62.87% | 26 | Aug 5, 2026 | |
| TYRA Tyra Biosciences | Maintained: Buy | $53 | $25.19 | +110.40% | 16 | Aug 5, 2026 | |
| GLUE Monte Rosa Therapeutics | Maintained: Buy | $37 → $27 | $16.00 | +68.75% | 11 | Aug 3, 2026 | |
| CBIO Crescent Biopharma | Maintained: Buy | $27 | $16.54 | +63.24% | 6 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 | $19.50 | +89.79% | 19 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 | $10.03 | +258.92% | 31 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $6.60 | +51.60% | 15 | Jul 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $3.48 | +216.55% | 18 | Jun 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 → $30 | $9.76 | +207.38% | 6 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $3.05 | +96.72% | 2 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 | $78.64 | +1.73% | 4 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 → $34 | $19.60 | +73.47% | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $8.25 | +203.21% | 10 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $6 | $0.6715 | +793.52% | 8 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $7 → $5 | $10.32 | -51.55% | 3 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 → $36 | $16.72 | +115.31% | 12 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $6 → $1 | $0.3637 | +174.95% | 4 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $4.17 | n/a | 13 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $6.94 | n/a | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $6 | $1.63 | n/a | 14 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.23 | n/a | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $67 | $136.29 | n/a | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $6 | $4.53 | n/a | 8 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $15.12 | n/a | 4 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $7 → $10 | $0.0001 | n/a | 2 | Mar 19, 2020 |
Tango Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $33 → $39
Current: $26.13
Upside: +49.25%
Replimune Group
Aug 7, 2026
Upgraded: Buy
Price Target: $12 → $19
Current: $15.31
Upside: +24.10%
Arcus Biosciences
Aug 6, 2026
Reiterated: Buy
Price Target: $41 → $43
Current: $28.88
Upside: +48.89%
Black Diamond Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $14
Current: $2.04
Upside: +587.96%
Revolution Medicines
Aug 6, 2026
Maintained: Buy
Price Target: $192 → $201
Current: $207.42
Upside: -3.10%
Arvinas
Aug 5, 2026
Maintained: Hold
Price Target: $11 → $12
Current: $8.81
Upside: +36.21%
IDEAYA Biosciences
Aug 5, 2026
Maintained: Buy
Price Target: $58 → $60
Current: $36.84
Upside: +62.87%
Tyra Biosciences
Aug 5, 2026
Maintained: Buy
Price Target: $53
Current: $25.19
Upside: +110.40%
Monte Rosa Therapeutics
Aug 3, 2026
Maintained: Buy
Price Target: $37 → $27
Current: $16.00
Upside: +68.75%
Crescent Biopharma
Jul 31, 2026
Maintained: Buy
Price Target: $27
Current: $16.54
Upside: +63.24%
Jul 29, 2026
Reiterated: Buy
Price Target: $37
Current: $19.50
Upside: +89.79%
Jul 28, 2026
Maintained: Buy
Price Target: $36
Current: $10.03
Upside: +258.92%
Jul 20, 2026
Maintained: Buy
Price Target: $10
Current: $6.60
Upside: +51.60%
Jun 4, 2026
Reiterated: Buy
Price Target: $11
Current: $3.48
Upside: +216.55%
May 27, 2026
Reiterated: Buy
Price Target: $38 → $30
Current: $9.76
Upside: +207.38%
May 18, 2026
Reiterated: Buy
Price Target: $6
Current: $3.05
Upside: +96.72%
May 18, 2026
Reiterated: Buy
Price Target: $80
Current: $78.64
Upside: +1.73%
May 14, 2026
Reiterated: Buy
Price Target: $29 → $34
Current: $19.60
Upside: +73.47%
May 14, 2026
Reiterated: Buy
Price Target: $25
Current: $8.25
Upside: +203.21%
May 14, 2026
Reiterated: Buy
Price Target: $7 → $6
Current: $0.6715
Upside: +793.52%
May 12, 2026
Maintained: Sell
Price Target: $7 → $5
Current: $10.32
Upside: -51.55%
May 8, 2026
Reiterated: Buy
Price Target: $45 → $36
Current: $16.72
Upside: +115.31%
Dec 19, 2025
Downgraded: Hold
Price Target: $6 → $1
Current: $0.3637
Upside: +174.95%
Aug 7, 2025
Maintained: Hold
Price Target: $4
Current: $4.17
Upside: n/a
Jul 14, 2025
Initiated Coverage: Buy
Price Target: $27
Current: $6.94
Upside: n/a
May 8, 2025
Maintained: Buy
Price Target: $7 → $6
Current: $1.63
Upside: n/a
Aug 14, 2024
Reiterated: Buy
Price Target: $8
Current: $2.23
Upside: n/a
Nov 19, 2021
Maintained: Buy
Price Target: $67
Current: $136.29
Upside: n/a
Mar 8, 2021
Maintained: Buy
Price Target: $7 → $6
Current: $4.53
Upside: n/a
Oct 5, 2020
Maintained: Buy
Price Target: $8
Current: $15.12
Upside: n/a
Mar 19, 2020
Downgraded: Hold
Price Target: $7 → $10
Current: $0.0001
Upside: n/a